Inequities in cancer drug development in terms of unmet medical need-Reference-Cited by-同舟云学术

Inequities in cancer drug development in terms of unmet medical need

Published:2022-06 Issue: Volume:302 Page:114953
ISSN:0277-9536
Container-title:Social Science & Medicine
language:en
Short-container-title:Social Science & Medicine

Author:

Barrenho Eliana^ORCID,Halmai Réka,Miraldo Marisa^ORCID,Tzintzun Iván^ORCID,Raïs Ali Setti^ORCID,Toulemon Léa^ORCID,Dupont Jean-Claude K.^ORCID,Rochaix Lise^ORCID

Publisher

Elsevier BV

Subject

History and Philosophy of Science,Health (social science)

Reference35 articles.

1. Ethics of phase 1 oncology studies: reexamining the arguments and data;Agrawal;JAMA,2003

2. A mapping of 115,000 randomized trials revealed a mismatch between research effort and health needs in non–high-income regions;Atal;J. Clin. Epidemiol.,2018

3. Future of rare diseases research 2017–2027: an IRDiRC perspective;Austin;Clin. Trans. Sci.,2018

4. Does global drug innovation correspond to burden of disease? The neglected diseases in developed and developing countries;Barrenho;Health Econ.,2019

5. A comparison of interventional clinical trials in rare versus non-rare diseases: an analysis of clinicaltrials.gov;Bell;Orphanet J. Rare Dis.,2014

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Availability and Access to Orphan Drugs for Rare Cancers in Bulgaria: Analysis of Delays and Public Expenditures;Cancers;2024-04-12

2. The role of patient organisations in research and development: Evidence from rare diseases;Social Science & Medicine;2023-12

3. Ethical challenges and opportunities in the development and approval of novel therapeutics for rare diseases;The Journal of Medicine Access;2023-01